Suppr超能文献

首例弥漫性大B细胞淋巴瘤治疗5年后持续性嵌合抗原受体T细胞(CAR T细胞)的女性自然健康怀孕病例。

First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma.

作者信息

Canty Ethan Abraham, Broderick Lori, Flaherty Daniel, Xavier Marin, Nasta Sunita D, Dajani Lina, White Andrew A

机构信息

Allergy, Asthma and Immunology, Scripps Green Hospital, La Jolla, California, USA

Allergy and Immunology, Rady Children's Hospital, San Diego, California, USA.

出版信息

J Immunother Cancer. 2025 Apr 1;13(4):e011092. doi: 10.1136/jitc-2024-011092.

Abstract

Chimeric antigen receptor T-cell (CAR T-cell) therapy has significantly advanced cancer treatments and remission rates; however, questions exist regarding the impacts on both fertility and immune effects on infants born to mothers who have undergone CAR T-cell therapy. There are no known reported cases of persistence of CAR T-cells after cancer therapy in pregnancy. Here, we present a case of a woman with relapsed refractory diffuse large B-cell lymphoma who undertook an experimental CAR T-cell therapy, had persistence of CAR T-cells 5 years after achieving remission, spontaneously became pregnant and delivered a healthy male infant. Our case provides an example of a healthy pregnancy despite the persistence of CAR T-cells and the resultant healthy newborn without evidence of immunologic or other health effects from the CAR T-cells.

摘要

嵌合抗原受体T细胞(CAR T细胞)疗法显著推动了癌症治疗并提高了缓解率;然而,对于接受过CAR T细胞疗法的母亲所生婴儿的生育能力和免疫影响仍存在疑问。目前尚无癌症治疗后妊娠期间CAR T细胞持续存在的报道病例。在此,我们报告一例复发性难治性弥漫性大B细胞淋巴瘤女性患者,她接受了实验性CAR T细胞疗法,缓解后5年CAR T细胞持续存在,随后自然受孕并产下一名健康男婴。我们的病例提供了一个尽管CAR T细胞持续存在但仍实现健康妊娠且新生儿健康的例子,未发现CAR T细胞产生免疫或其他健康影响的证据。

相似文献

4
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Clin Cancer Res. 2021 Jan 15;27(2):473-484. doi: 10.1158/1078-0432.CCR-20-1457. Epub 2020 Oct 7.
6
Neonatal Outcomes following 2 Cases of Maternal CAR-T Therapy for High-Grade B-Cell Lymphoma.
Neonatology. 2025;122(2):146-150. doi: 10.1159/000542016. Epub 2024 Nov 7.

本文引用的文献

1
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Blood Adv. 2023 Nov 28;7(22):6990-7005. doi: 10.1182/bloodadvances.2023011399.
2
CAR T-cell therapy in autoimmune diseases.
Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22.
4
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
5
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma.
Int J Mol Sci. 2023 Mar 16;24(6):5688. doi: 10.3390/ijms24065688.
7
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15.
8
Fertility and CAR T-cells: Current practice and future directions.
Transplant Cell Ther. 2022 Sep;28(9):605.e1-605.e8. doi: 10.1016/j.jtct.2022.06.002. Epub 2022 Jun 12.
9
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
10
Immunotherapy for cancer treatment during pregnancy.
Lancet Oncol. 2021 Dec;22(12):e550-e561. doi: 10.1016/S1470-2045(21)00525-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验